1 Min Read
NEW YORK, Jan 28 (Reuters) - Keryx Biopharmaceuticals Inc : * Keryx Biopharma jumps 46.4 percent to $5.02 in premarket after kidney disease drug meets late-stage trial goal
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.